| HOME >> BIOLOGY >> TECHNOLOGY |
About Epidauros (http://www.epidauros.com)
Epidauros investigates the genetic factors that influence a person's response to a drug and makes drug development and therapy safer, more efficient and more predictive. The company has established itself as a worldwide leading Pharmacogenetic Research Organization (PRO) providing innovative, integrated and value-added solutions to an international customer base consisting of pharmaceutical companies, CROs and other companies acting in the field of health care.
Thanks to the pharmacogenetic expert knowledge of its qualified scientific team, Epidauros is a competent partner for contract research to reveal new pharmacogenetic targets and polymorphisms that impact drug response. In addition, Epidauros has brought together a network of competent partners to do research and has established its own intellectual property base in the field.
The company is located in Bernried near Munich and was founded as a pioneering company in the field of pharmacogenetics in 1997.
For More Information
Clinical Data
John Schultz
+1-617-527-9933 ext. 3350
Epidauros
Michael Lutz, Ph.D.
+49 (0)8158 9985 71
The Ruth Group
Sara Ephraim (investors)
+1-646-536-7002
Jason Rando (media)
+1-646-536-7025
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains certain forward-
'/>"/>
| SOURCE Clinical Data, Inc. Copyright©2007 PR Newswire. All rights reserved |